Molecular glue discovery is a mechanism-deconvolution workflow as much as a screening workflow. It connects a compound to the ligase, neosubstrate, interface, and degradation pathway before a hit can be treated as a validated degrader.
Run phenotype-first, ligase-first, or interface-guided screens and flag compounds with unusual, durable, or proteasome-dependent activity.
Establish degradation-pathway dependence with proteasome and neddylation rescue, transcript versus protein kinetics, and washout studies.
Identify the ligase and recruited neosubstrate through genetics, proteomics, and compound-dependent recruitment assays.
Model the composite interface and validate it with resistance mutations, mutagenesis, and molecular dynamics.
Rank hits by evidence convergence across phenotype, genetics, proteomics, structure, and selectivity—not phenotype alone.
A molecular-glue hit rarely needs every capability at once. Start with what is unknown—chemical tractability, ligase identity, neosubstrate recruitment, or interface persistence—and build the next study around the result that would most clearly confirm or reject the mechanism.
Screen compounds in a disease-relevant cellular assay, then identify hits with unusual, durable, or proteasome-dependent activity. This route can reveal unexpected biology but demands strong genetic, proteomic, and chemical tools.
Begin with a compound family known to bind an E3 substrate receptor such as CRBN or DCAF15, and profile analogs for induced binding and degradation. The ligase is defined, but neosubstrate selectivity must still be resolved.
Use a known ternary structure, degron motif, or resistance mutation to design molecules that complement the composite surface. This is the most hypothesis-driven route but depends on suitable structural and chemical starting points.
Deconvolution moves from genetic determinants to physical recruitment and structural resolution, with each step confirming causality before the next is built on top of it.
Discuss Your Study DesignResistance selection or CRISPR screening can reveal ligase components, proteasome factors, substrate regulators, transporters, or pathway modifiers.
Quantitative proteomics identifies early depleted proteins; ubiquitin-remnant profiling can support direct pathway engagement.
Biophysical, biochemical, and cellular proximity assays assess compound-dependent complex formation.
Ligase knockout, substrate rescue, resistant interface variants, competition, and proteasome rescue connect recruitment to degradation and phenotype.
Structural biology, docking, molecular dynamics, and mutagenesis explain how the compound complements the interface.
A hit can be chased down many paths. Keeping ligase identity, substrate selectivity, and interface geometry connected prevents each assay from being read in isolation.
A single decisive experiment can be scoped quickly; a full deconvolution workflow runs across several stages with checkpoints.
| Evidence layer | Advancement signal | Major warning |
|---|---|---|
| Phenotype | Reproducible, disease-relevant, temporally follows target loss | Activity tracks with general stress or cytotoxicity |
| Genetics | Specific ligase components and substrate interface determine response | Only broad proteasome genes emerge |
| Proteomics | Early selective depletion with coherent recovery | Widespread protein loss before the proposed substrate changes |
| Recruitment | Compound-dependent ternary formation in orthogonal assays | Signal depends on one assay orientation or high aggregation-prone concentrations |
| Structure | Model explains SAR and resistance mutations | Single unconstrained pose is treated as proof |
| Exposure | Cellular concentration supports the observed mechanism | Nominal potency conflicts with free intracellular exposure |
| Selectivity | Direct substrates and downstream effects are distinguishable | Unmapped neosubstrates create safety uncertainty |
The compound may cause broad proteostasis stress; use time-resolved proteomics and genetics.
Measure RNA and translation to separate degradation from expression changes.
The ligase may regulate an upstream pathway; test compound-dependent physical complex formation.
Revisit the pose ensemble and test interface mutations rather than adding simulation time only.
Use resistant variants and selective analogs to identify which substrate drives efficacy and toxicity.
Structures, purity, stereochemistry, and matched inactive controls.
Cell model, ligase abundance, and time-resolved transcript, protein, ubiquitination, and phenotype measurements.
Genetic determinants, orthogonal recruitment evidence, and structural models with restraints and uncertainty.
Direct-substrate shortlist separated from downstream effects, plus a ranked optimization plan.
Aryl sulfonamides including E7820 and indisulam recruit the splicing factor RBM39 to the DCAF15 substrate receptor. The compound occupies a shallow DCAF15 surface, and extensive DCAF15–RBM39 contacts contribute substantially to recruitment.
CC-885 recruits GSPT1 to CRBN, showing how changes in a ligase-binding chemical class can redirect neosubstrate recognition. This does not imply every ligase-binding compound is a glue—it defines an experimental strategy.
The right experiment depends on how far a hit has been characterized—these answers clarify what counts as validation.
Docking can prioritize hypotheses when the ligase, substrate, and interface are sufficiently defined, but it cannot establish cellular degradation or phenotype causality. Weak composite interfaces, protein flexibility, unknown neosubstrates, and sparse training data make experimental screening and mechanism deconvolution essential.
No. Proteasome dependence narrows the mechanism but can also arise from broad proteostasis disruption or indirect pathway effects. A validated glue requires evidence for a compound-induced interaction, a specific ligase–substrate relationship, ubiquitination, selective protein loss, and linkage to the observed phenotype.
Use early time-resolved quantitative proteomics, ubiquitination measurements, genetic resistance, direct recruitment assays, and analog comparisons. Later changes should be separated from direct substrates, and tissue expression and exposure should then be considered because a selective profile in one cell model may not transfer to another biological context.
Share the target, available ligands, preferred E3 systems, structural data, assays, and project constraints. CD ComputaBio will propose a fit-for-purpose analysis across the stages you need. Related services: PROTAC Design and Development Service, Molecular Docking Service, Molecular Dynamics Simulation.
Submit your project details below, and our team will respond within 24 hours.
Talk to our technical team about your project!
I Want To Talk
